NCT03943576View on ClinicalTrials.gov

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

April 27, 2022

Study Completion Date

March 22, 2023

Conditions
Knee Osteoarthritis
Interventions
DRUG

GXCPC1

The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)

DEVICE

HA

Hya Joint Plus synovial fluid supplement 3mL

Trial Locations (1)

30261

GWOXI Stem Cell Applied Technology Co., Ltd., Hsinchu

All Listed Sponsors
lead

Gwo Xi Stem Cell Applied Technology Co., Ltd.

INDUSTRY

NCT03943576 - Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter